HomeCompareXEPRF vs PFE

XEPRF vs PFE: Dividend Comparison 2026

XEPRF yields 20000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XEPRF wins by $52481917574412746752.00M in total portfolio value
10 years
XEPRF
XEPRF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full XEPRF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — XEPRF vs PFE

📍 XEPRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXEPRFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XEPRF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XEPRF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XEPRF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, XEPRF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XEPRF + PFE for your $10,000?

XEPRF: 50%PFE: 50%
100% PFE50/50100% XEPRF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

XEPRF
No analyst data
Altman Z
-34.2
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XEPRF buys
0
PFE buys
0
No recent congressional trades found for XEPRF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXEPRFPFE
Forward yield20000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$52481917574412746752.00M$49.6K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$26,258.71
Total dividends collected$52448189483771600896.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: XEPRF vs PFE ($10,000, DRIP)

YearXEPRF PortfolioXEPRF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,010,700$2,000,000.00$9,153$693.39+$2.00MXEPRF
2$377,983,225$375,831,775.70$8,593$849.25+$377.97MXEPRF
3$66,433,479,469$66,029,037,418.28$8,336$1,066.78+$66433.47MXEPRF
4$10,916,985,471,987$10,845,901,648,955.73$8,437$1,384.80+$10916985.46MXEPRF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$9,013$1,875.40+$1677384363.76MXEPRF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$10,306$2,680.72+$240985175079.13MXEPRF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$12,820$4,101.38+$32373573631143.68MXEPRF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$17,673$6,826.70+$4066766648320630.00MXEPRF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$27,543$12,591.86+$477730483406513344.00MXEPRF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$49,560$26,258.71+$52481917574412746752.00MXEPRF

XEPRF vs PFE: Complete Analysis 2026

XEPRFStock

Xemplar Energy Corp. engages in the acquisition, exploration, and development of marble concession, uranium, and bentonite deposits. The company holds a 60% interest in a marble concession, which covers an area of 168.469 acres located in Markandi District, Abbotabad, as well as two marble concession prospecting licenses covering an area of 288 acres located in Bakot Nala and Bagwa Kas areas, Pakistan. It also holds a 100% interest in the Cape Cross and Warmbad properties that are located in Namibia. The company was formerly known as Consolidated Petroquin Resources Limited and changed its name to Xemplar Energy Corp. in July 2005. Xemplar Energy Corp. was incorporated in 1979 and is headquartered in Vancouver, Canada.

Full XEPRF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this XEPRF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XEPRF vs SCHDXEPRF vs JEPIXEPRF vs OXEPRF vs KOXEPRF vs MAINXEPRF vs JNJXEPRF vs MRKXEPRF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.